Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
2X-121 · 1 trial · 1 indication
To evaluate the optimal dose of 2X-121 as single agent therapy at 600 mg daily compared to 800 mg daily.
| Arm | Type | Description |
|---|---|---|
| Drug: 2X-121 600 mg | EXPERIMENTAL | 2X-121 will be administered daily as 600 mg (200 mg 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle. |
| Drug: 2X-121 800 mg | EXPERIMENTAL | 2X-121 will be administered 800 mg (400 mg (2 x 200 mg) 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle. |
| Name | Type | Description |
|---|---|---|
| 2X-121 | DRUG | 2X-121 will be administered daily as 600 mg (200 mg 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle. |
Inclusion Criteria: 1. Signed informed consent form. 2. Age 18 years or older. 3. Histologically or cytologically documented epithelial ovarian, fallopian tube, or primary peritoneal tumors, with high-grade serous or endometrioid, or predominantly serous/endometrioid histology (independent of BRCA1...
Top 20 of 60 competitors
2X-121 is an investigational small molecule being studied for the treatment of recurrent, advanced ovarian cancer. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
2X-121 is an inhibitor that targets TNKS2, TNKS, PARP2, and PARP1. These are enzymes involved in DNA repair pathways, and inhibiting them is the proposed mechanism of action for the drug's anti-tumor effect.
2X-121 is being developed by Allarity Therapeutics, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol ALLR.
2X-121 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies for any use.
2X-121 is being evaluated in a Phase 2 clinical trial with the identifier NCT03878849. This trial is investigating the anti-tumor effect of 2X-121 in patients with recurrent, advanced ovarian cancer and is currently recruiting participants in the United States.